nalbuphine + dexmedetomidine

Nalbuphine + dexmedetomidine is a combination therapy being evaluated for its efficacy in improving the quality of recovery and reducing emergence agitation in elderly patients following general anesthesia. Nalbuphine is a mixed opioid agonist-antagonist that acts as a potent agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors, providing analgesia with a lower risk of respiratory depression compared to pure mu-agonists. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that provides sedation, sympatholysis, and analgesia without significant respiratory depression. The combination is intended to stabilize hemodynamics and mitigate the high sensitivity to external stimulation often seen during the recovery period of general anesthesia, particularly in elderly populations with organ dysfunction.

Other names

dexmedetomidine combined with nalbuphine